SCHEMBL721701

SCHEMBL721701

Cc1cccc2cc([C@H](C)NC(=O)C(F)(F)F)c(Cl)nc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.41
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ATM Q13315 1/20 0.38
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721702 1.00 KDR (0.41) KDRMAPTMEN1KMT2ANPC1
SCHEMBL844461 0.86 MAPT (0.46) KDRMAPTMEN1KMT2ANPC1
SCHEMBL713467 0.81 TSHR (0.43) KDRMAPTMEN1KMT2ANPC1
SCHEMBL863903 0.81 TSHR (0.43) KDRMAPTMEN1KMT2ANPC1
SCHEMBL5302 0.76 GPR139 (0.39) MAPTMEN1KMT2ANPC1GAA
SCHEMBL2115559 0.76 MAPT (0.43) KDRMAPTMEN1KMT2ANPC1
SCHEMBL1880475 0.75 DRD4 (0.45) KDRMAPTMEN1KMT2ANPC1
SCHEMBL1886074 0.75 DRD4 (0.45) KDRMAPTMEN1KMT2ANPC1
SCHEMBL26529514 0.74 LMNA (0.47) KDRMAPTMEN1KMT2ANPC1
SCHEMBL17530802 0.74 SOS1 (0.42) MAPTMEN1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 KDR 437/4885MAPT 1229/4885MEN1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.